Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03497767
Title A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Trans Tasman Radiation Oncology Group
Age Groups: adult | senior
Covered Countries

No variant requirements are available.